Latest news
AKBA: Vafseo revenue and patient growth accelerated, offsetting AURYXIA declines amid robust pipeline progress - TradingViewTradingView · Wed, 05 Aug 2026 21:53:37 GMTAkebia Q2 2026 earnings: Vafseo growth did not offset Auryxia decline - TradingKeyTradingKey · Wed, 05 Aug 2026 21:21:47 GMTAkebia Q2 revenue falls on lower Auryxia sales - TradingViewTradingView · Wed, 05 Aug 2026 20:45:56 GMTAkebia Therapeutics 2Q 2026: Revenue $49.1M, EPS $(0.03) — 10-Q Summary - TradingViewTradingView · Wed, 05 Aug 2026 20:26:35 GMTAKBA: Vafseo's strong growth offset Auryxia's decline, but total revenues and net income fell year-over-year - TradingViewTradingView · Wed, 05 Aug 2026 20:17:59 GMT